OncoMatch/Clinical Trials/NCT06093438
Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer
Is NCT06093438 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Toripalimab for cervical cancer.
Treatment: Toripalimab — To explore the efficacy of incorporating neoadjuvant immunotherapy into neoadjuvant chemotherapy in locally advanced cervical cancer patients with high risk of recurrence.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Disease stage
Required: Stage IIIB, IIIC, IVA
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: any prior treatment
Patients received any form of treatment before enrollment
Lab requirements
Blood counts
Hemoglobin ≥ 9.0 g/dl; Neutrophils ≥ 2000 cells/μl; Leukocytes ≥ 4 × 10^9/L; Platelets ≤ 100 × 10^9/L
Kidney function
Serum urea nitrogen (BUN) ≤ 1.5 × upper normal limit (UNL); Serum creatinine (Cr) ≤ 1.5 × upper normal limit (UNL)
Liver function
Serum ALT/AST ≤ 2.5×UNL; Serum Total bilirubin ≤ 1.5× UNL
Cardiac function
No obvious arrhythmia, myocardial ischemia, severe atrioventricular block, cardiac insufficiency or severe heart valve disease
Adequate hematological, renal and hepatic functions: ... Impaired hematological, renal or hepatic functions: Hemoglobin < 9.0 g/dl, Neutrophils < 2000 cells/μl; Leukocytes < 4 × 10^9/L; Platelets > 100 × 10^9/L; Serum ALT/AST > 2.5×UNL; Serum Total bilirubin > 1.5× UNL; Serum urea nitrogen (BUN) > 1.5 × upper normal limit (UNL); Serum creatinine (Cr) > 1.5 × upper normal limit (UNL)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify